Rivaroxaban News and Research

RSS

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in JAMA.

31 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Oral anticoagulants benefit patients with atrial fibrillation at intermediate stroke risk

Oral anticoagulant therapy lowered the risk of adverse clinical events compared with no anticoagulation in patients with atrial fibrillation at intermediate stroke risk, according to results from the SINGLE-AF trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

28 Aug 2026

Antihistamines show modest benefits for long Covid fatigue treatment

Over-the-counter antihistamines and a prescription anti-inflammatory drug both have a small benefit in reducing long Covid fatigue among people receiving care from specialist long Covid clinics, according to new findings from a large clinical trial led by UCL and UCLH.

8 Jul 2026

Apixaban reduces complications, helps older adults spend more time at home after blood clots

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence.

27 Apr 2026

Apixaban safer than rivaroxaban for treating venous thrombosis

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

11 Mar 2026

New guidelines outline comprehensive care for acute pulmonary embolism

Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical.

19 Feb 2026

Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

6 Feb 2026

Anticoagulants increase bleeding post-ablation with no added stroke benefit

A minimally invasive heart procedure to correct irregular heart rhythms called catheter ablation may reduce the risk of stroke enough that some patients can discontinue blood thinners, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

One-month dual therapy strategy offers advantages for AFib patients and clinicians

New research found a simplified clot-preventing medication regimen following stent placement in adults with atrial fibrillation was just as safe and effective in preventing strokes, heart attack and death, when compared to a standard year-long treatment regimen, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Stopping oral anticoagulation reduces risk after successful atrial fibrillation ablation

Discontinuing oral anticoagulation (OAC) therapy resulted in a lower risk of a composite of stroke, systemic embolism or major bleeding than continuing OAC therapy in patients who had successful ablation for atrial fibrillation at least 12 months previously, according to results from a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in The Journal of the American Medical Association.

3 Sep 2025

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based care in patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New guidance aims to improve blood clot prevention in chronic limb-threatening ischemia patients

A new statement from leading heart and blood vessel experts in Europe is providing clinical guidance for treatments to prevent blood clots in patients with a serious condition called chronic limb-threatening ischaemia (CLTI), after they have had procedures to restore blood flow in their lower limbs.

19 Jun 2025

New and updated clinical practice guidelines released for treatment of pediatric venous thromboembolism

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released new and updated clinical practice guidelines for the treatment of pediatric venous thromboembolism (VTE).

27 May 2025

Long-term study confirms safety and effectiveness of rivaroxaban for children

Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer.

23 May 2025

Rivaroxaban shown to be a viable alternative to warfarin for left ventricular thrombus

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar patients who received standard treatment with warfarin, an older blood-thinning drug.

29 Mar 2025

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.

19 Feb 2025

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025

New Factor XI inhibitor shows superior safety in treating atrial fibrillation

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to concerns of increased risk of bleeding complications.

22 Jan 2025

Reduced blood thinner dose may lower bleeding risk and hospital visits

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.

19 Dec 2024